Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 vs Viatris Inc — how do they compare? Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $46.99, while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 pays none, and Viatris Inc is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals.
| USOI | VTRS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.17 | $17.39 |
52-Week Low | $42.27 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Signals from Pluang's Aura AI — not financial advice
USOI, the Credit Suisse X-Links Crude Oil Shares Covered Call ETN, trades at $46.84, up 0.09% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The instrument's exceptionally high yield, cited as over 30% by 24/7 Wall Street on 2026-05-19, draws investor attention amid oil market volatility driven by geopolitical events like the Iran War, as reported on 2026-04-26. Key support sits at $45 with resistance at $47.
The outlook hinges on crude oil price movements and covered call strategy performance, offering high income potential but carrying significant risks from oil volatility and the ETN structure, which differs from traditional ETFs. Investors face concentration risk in energy markets and potential capital erosion if oil trends lower.
No Aura AI signal available yet.
Trailing returns across standard periods
USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →